In an editorial published in the New England Journal of Medicine, University of Michigan Health hepatologist Anna S. Lok, M.D ...
The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new drug may cure 1 in 5 of those cases.
A new drug has cured 20% of patients with a chronic, cancer-causing disease — which was previously incurable. A viral ...
Two replicate phase 3 randomized controlled trials involving patients with chronic hepatitis B virus (HBV) infection demonstrate a functional cure after the discontinuation of conventional long-term ...
In HepG2.117 cells, ALG-001075 achieved HBV DNA EC50 0.64 nM, outperforming canocapavir (5.8 nM) and neracorvir (24 nM) with ...
New research implies that a first-of-its-kind drug for hepatitis B could allow some patients to stop treatment without showing signs of the dangerous virus.
Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a ...
Two cross-sectional, one validation cohort, and meta-analyses were used to explore the relationship between HBV replication and liver inflammation. Spearman analysis, multiple linear regression, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results